Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of the Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Initially Unresectable Biliary Tract Cancer

NCT04984980 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04984980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04984980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of the Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Initially Unresectable Biliary Tract Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2020
Completion date
July 31, 2023
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract carcinoma, initially unresectable